Ponatinib

An ARIAD-developed medicine.

About ponatinib

Internally discovered at ARIAD, ponatinib is a BCR-ABL inhibitor that also selectively inhibits certain other tyrosine kinases in preclinical studies, including FLT3, RET, KIT and the members of the FGFR, PDGFR and VEGFR families of kinases.